The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations
Open Access
- 5 August 2019
- journal article
- review article
- Published by MDPI AG in Medical Sciences
- Vol. 7 (8) , 85
Abstract
Multi-parametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) using prostate-specific membrane antigen (PSMA) targeting ligands have been adopted as a new standard of imaging modality in the management of prostate cancer (PCa). Technological advances with hybrid and advanced computer-assisted technologies such as MR/PET, MR/US, multi-parametric US, and robotic biopsy systems, have resulted in improved diagnosis and staging of patients in various stages of PCa with changes in treatment that may be considered “personalized”. Whilst newer clinical trials incorporate these novel imaging modalities into study protocols and as long-term data matures, patients should be made aware of the potential benefits and harm related to these technologies. Published literature needs to report longer-term treatment efficacy, health economic outcomes, and adverse effects. False positives and negatives of these imaging modalities have the potential to cause harm and the limitations of these technologies should be appreciated. The role of a multi-disciplinary team (MDT) and a shared-decision-making model are important to ensure that all aspects of the novel imaging modalities are considered.Keywords
This publication has 55 references indexed in Scilit:
- Three-Tesla Magnetic Resonance–Guided Prostate Biopsy in Men With Increased Prostate-Specific Antigen and Repeated, Negative, Random, Systematic, Transrectal Ultrasound Biopsies: Detection of Clinically Significant Prostate CancersEuropean Urology, 2012
- Active surveillanceCurrent Opinion in Urology, 2012
- ESUR prostate MR guidelines 2012European Radiology, 2012
- [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECHEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Risk-Based Management of Prostate CancerNew England Journal of Medicine, 2011
- Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate CancerJournal of Clinical Oncology, 2010
- Salvage Radiotherapy for Recurrent Prostate Cancer After Radical ProstatectomyJAMA, 2004
- Upregulation of prostate-specific membrane antigen after androgen-deprivation therapyUrology, 1996
- Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigenUrologic Oncology: Seminars and Original Investigations, 1995
- Nuclear Magnetic Resonance Imaging of the ProstateBritish Journal of Urology, 1982